Skip to Content

Dolasetron Mesylate Injection

Last Updated: March 8, 2017
Status: Current

Products Affected - Description

Anzemet intravenous injection, Validus Pharmaceuticals
12.5 mg, 0.625 mL single dose vial, 6 count (NDC 00088-1208-06)

100 mg, 5 mL single dose vial, 1 count (NDC 00088-1206-32)
500 mg, 25 mL multiple dose vial, 1 count (NDC 00088-1209-26)

Reason for the Shortage

  • Validus Pharmaceuticals acquired Anzemet injection from Sanofi US in December 2015.
  • Validus Pharmaceuticals has temporarily discontinued all Anzemet injection presentations and cannot estimate a resupply date.

Available Products

There are no presentations available.

Estimated Resupply Dates

Validus Pharmaceuticals has temporarily discontinued all Anzemet injection presentations and the company cannot estimate a resupply date. The company does not expect product before the second half of 2017.

Related Shortages

Updated

March 8, 2017; November 29, August 24, July 7, April 5, February 29, 2016, University of Utah, Drug Information Service. Copyright 2017, Drug Information Service, University of Utah, Salt Lake City, UT.

Hide